Relapsing MS Patients May Fare Better on Zeposia Than Aubagio multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Novartis’ MS therapy Kesimpta wins NICE backing
21st April 2021
Novartis’ Kesimpta has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients.
Kesimpta (ofatumumab) is the first self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS with active disease, according to Novartis.
In its final appraisal document, NICE recommended Kesimpta for the treatment of adult patients with RRMS with active disease, defined by clinical or imaging features.
NICE concluded that Kesimpta is a cost-effective treatment that can be used as a first-line therapy or following the use of other treatments for people with RRMS.